Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion.

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion.

Benzinga

Analyst Ratings for Amgen

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all regular shares that are available for trading.

Benzinga

2 Buy-Rated Dow Jones Stocks to Add to Your Portfolio Now

Investors’ concerns over a potential recession due to the Fed’s policy measures to control inflation wreaked havoc on the stock market over the past few weeks. However, the recovery of the major stock-market indexes in the last trading session indicates that the market could be leveling off. With the possibility…

StockNews.com

Executives Sell More Than $220M Of 3 Stocks

US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

This Is What Whales Are Betting On Amgen

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analyzing Amgen's Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of all regular shares that are available for trading.

Benzinga

Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of $124.75 billion.

Benzinga

Check Out What Whales Are Doing With AMGN

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.

Benzinga

Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at $235.12 per share. A move to $260.00 would account for a 10.58% increase from the current…

Benzinga

Amgen's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.

Benzinga

Where Amgen Stands With Analysts

Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:

Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.

Benzinga

Recap: Amgen Q1 Earnings

Amgen (NASDAQ:AMGN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 2.41%, reporting an EPS of $4.25 versus an estimate of $4.15.

Benzinga

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Molecular Partners AG's (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review. MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming…

Benzinga

Earnings Preview: Amgen

Amgen (NASDAQ:AMGN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Amgen will report an earnings per share (EPS) of $4.15.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $100 In Amgen 15 Years Ago, Here's How Much You Would Have Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.31% on an annualized basis producing an average annual return of 9.87%. Currently, Amgen has a market capitalization of $136.97 billion.

The Independent UK

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Exclusive: British government accused of indirectly helping to fund Putin’s war with £294m contracts

Benzinga

Where Amgen Stands With Analysts

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Benzinga

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

Benzinga

$1000 Invested In Amgen 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 13.98%. Currently, Amgen has a market capitalization of $136.43 billion.

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.42% on an annualized basis.

Benzinga

A Bullish Sign Appears On Amgen's Chart

If history is any guide, there may be good fortune ahead for shares of Amgen (NASDAQ:AMGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rivian Automotive Inc

100 stories

Visa Inc

98 stories

Internal Revenue Service

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.